UNSPSC 51283608: Rifamycin b diethylamide

This classification denotes an antitubercular agent with the molecular formula C43H58N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TS121H7U7E, chemically known as rifamycin, 4-o-(2-(diethylamino)-2-oxoethyl)-, but more generally known as rifamycin b diethylamide, which bears US NIH Compound Identifier 5382104. European Medicines Agency schedules rifamycin b diethylamide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin b diethylamide under HS 29419000. SMILES: CCN(CC)C(=O)COC1CC2C(C3C1C4C(C(C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)N2)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283608 Rifamycin b diethylamide is a Commodity code that carries a significant mislabeling problem in recent state and local activity. The three recent opportunities posted under this code solicited naloxone and drug deactivation systems, pharmaceutical prescriptions and direct-to-manufacturer contracting, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products — none of which align with rifamycin b diethylamide, a specific antibiotic compound used in tuberculosis and related treatments. The code shows little relevant activity targeting the pharmaceutical product it nominally describes; the opportunities instead reflect broad-based pharmaceutical procurement, emergency medical supplies, and pharmacy benefit management across state health agencies, county health systems, municipal fire departments, and cooperative purchasing alliances.

The recent opportunities span Florida, Texas, and Minnesota through diverse issuing bodies: Seminole County, Florida (community health procurement); the Texas Health and Human Services Commission (pharmacy benefit program redesign via RFI); the City of Tampa Fire Department (medical and first aid supplies via IFB with a $700,000 estimated value and SLBE set-aside); and the Minnesota Multistate Cooperative Purchasing Alliance (generic pharmaceuticals and OTC products via RFP due March 26, 2026, administered across multiple state and local jurisdictions including Oregon). The mislabeling across these solicitations — none of which target rifamycin specifically — suggests either systematic catalog error or vendor tagging drift in state and local procurement systems. Business development professionals should verify actual pharmaceutical demand and product specifications before pursuing opportunities tagged to this code, as the code's nominal scope and recent posting practice diverge materially.